The prevalence of hepatitis B co-infection in a South African urban government HIV clinic.
OBJECTIVE
There are an estimated 350 million hepatitis B carriers worldwide. In South Africa the prevalence of mono-infection with hepatitis B has been estimated to range from 1% in urban areas to approximately 10% in rural areas. The exact prevalence of hepatitis B in the HIV-infected population has not been well established. Hepatitis B screening is not standard practice in government HIV clinics. Co-infection with hepatitis B and HIV can influence antiretroviral treatment and prognosis of both diseases. The purpose of this study was to evaluate the prevalence of hepatitis B/HIV coinfection.


METHODS
This is believed to be the first prospective observational report on the prevalence of hepatitis B/HIV co-infection in South Africa. Patients on whom hepatitis B serological tests could not have been done previously were recruited from an HIV clinic in a regional hospital in Johannesburg. Standard hepatitis B serological tests were performed.


RESULTS
Five hundred and two participants were screened. The cohort's average age was 37 +/- 9 years and the average CD4 count was 128 cells/pi. Twenty-four (4.80%) were hepatitis B surface antigen positive. Nearly half (47%) of the participants showed some evidence of hepatitis B exposure. The risk of hepatitis B co-infection was not significantly different when analysed in terms of sex, race, CD4 count or age. Liver function tests were not a good predictor of hepatitis B infection.


CONCLUSIONS
The rate of hepatitis B infection, as defined by hepatitis B surface antigen positivity in HIV-infected individuals in urban South Africa was 5 times the rate in people who were not HIV-infected. A 5% rate of hepatitis B/HIV co-infection is a reason to increase the accessibility of tenofovir/emtricitabine (Truvada) for first-line treatment for this population.
Firnhaber
Cynthia
C
Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg. cfirnhaber@witshealth.co.za
Reyneke
Anne
A
Schulze
Doreen
D
Malope
Babatyi
B
Maskew
Mhairi
M
MacPhail
Patrick
P
Sanne
Ian
I
Di Bisceglie
Adrian
A
D000328:Adult; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D015897:Comorbidity; D005260:Female; D015658:HIV Infections / Q000453:epidemiology* / Q000503:physiopathology; D006509:Hepatitis B / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D008297:Male; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013019:South Africa / Q000453:epidemiology; D014505:Urban Population / Q000706:statistics & numerical data*
D006514:Hepatitis B Surface Antigens
Clin Infect Dis. 2004 Jul 1;39(1):129-32
15206064
Br Med J (Clin Res Ed). 1986 Nov 22;293(6558):1339-41
3024771
AIDS. 2005 Feb 18;19(3):221-40
15718833
J Clin Virol. 2006 Jan;35(1):14-20
15916918
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S98-103
14986281
Lancet. 1984 Jun 2;1(8388):1210-2
6144925
East Afr Med J. 2000 Jan;77(1):13-5
10944831
Liver Int. 2005 Apr;25(2):201-13
15780040
J Infect Dis. 2004 Apr 1;189(7):1185-92
15031786
J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):869-75
15213572
Clin Infect Dis. 2003 Dec 15;37(12):1678-85
14689351
Br Med J (Clin Res Ed). 1986 May 31;292(6533):1440-2
3087462
AIDS. 2007 Jun 19;21(10):1301-8
17545706